We are pleased to share that Jeremy Rich, MD, MHS, MBA, deputy director, UPMC Hillman Cancer Center, has been selected and agreed to serve as interim director, effective Aug. 7, to see us through the transition period with Robert Ferris, MD, PhD’s departure as director on the horizon and our national search for a new director of UPMC Hillman Cancer Center underway.
UPMC Hillman, the largest academically associated clinical oncology network in the United States, is one of the National Cancer Institute (NCI)-designated comprehensive cancer centers.
Dr. Rich, who joined UPMC Hillman in early 2021, pledges to continue to be a facilitator, collaborator, and servant leader in his interim director role. He looks forward to continuing to position UPMC Hillman as a national thought leader in cancer care, prevention, and research.
Both a board-certified neuro-oncologist and renowned physician-scientist, Dr. Rich specializes in diagnosing and treating brain tumors, with a focus on primary and metastatic brain tumors.
He received his MD from Duke University and completed his neurology residency at The Johns Hopkins Hospital and a fellowship in neuro-oncology at Duke University Medical Center. He also holds a Master of Health Sciences in Clinical Leadership from Duke and an MBA from Baldwin Wallace University.
Prior to his tenure at UPMC Hillman, Dr. Rich served as a professor of medicine, director of the Brain Tumor Institute, and co-director of the Solid Tumor Therapeutics Program at the University of California San Diego. Earlier in his career, he was chair of the Department of Stem Cell Biology and Regenerative Medicine at Cleveland Clinic. Dr. Rich has served on the Council for the American Association of Physicians and as lead investigator of the American Cancer Society Cancer Stem Cell Consortium.
